Adaptive Biotechnologies Corp is projected to report Q2 2026 revenue of $66.27 million and a consensus EPS loss of $0.13, with shares currently trading at $22.27 against an average analyst price target of $22.29.
Investors are closely monitoring the growth of clonoSEQ test volumes and overall Minimal Residual Disease (MRD) segment revenue as the company’s primary valuation driver.
Following a record-breaking first quarter where MRD revenue climbed 53% year-over-year, the company raised its full-year guidance and signaled a clearer path toward profitability.
Analysts remain focused on whether the company can maintain this momentum while executing the strategic separation of its Immune Medicine business and reducing its cash burn.